MedTrace Logo

AZD2423 Single Ascending Dose Study in Healthy Japanese Subjects

NCT00970775 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2010-03-18

No results posted yet for this study

Summary

This is a Phase I, single centre, randomised, double-blind, placebo-controlled, parallel group study to assess the safety, tolerability and pharmacokinetics of AZD2423 following single ascending dose administration to healthy Japanese subjects.

Conditions

  • Healthy Volunteer

Interventions

DRUG

AZD2423

oral solution, single dose

DRUG

Placebo

oral solution,single dose

Sponsors & Collaborators

Principal Investigators

  • Ulrike Lorch, MD MFPM FRCA · Richmond Pharmacology Limited

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00970775 on ClinicalTrials.gov